Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

30
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

608
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
608
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

714
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
714

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical, in vitro, and in vivo evidence of WAPL as a cohesinopathy-associated gene and phenotypic driver of 10q22.3q23.2 genomic disorder.

American journal of human genetics·2026
Same author

Loss of TMEM65 in mice causes mitochondrial disease mediated by mitochondrial Ca<sup>2</sup>.

Nature communications·2026
Same author

Clinical, <i>in vitro</i>, and <i>in vivo</i> evidence of <i>WAPL</i> as a novel cohesinopathy gene and phenotypic driver of 10q22.3q23.2 genomic disorder.

medRxiv : the preprint server for health sciences·2026
Same author

Immunoregulatory gene <i>GIMAP6</i> suppresses lethal atherosclerotic vasculopathy and ischemic heart failure.

bioRxiv : the preprint server for biology·2026
Same author

Benefits and Barriers of Combined Aerobic and Strength Training on Medical Students' Psychological Wellbeing.

American journal of lifestyle medicine·2025
Same author

A murine model lacking Lyst recapitulates Chediak-Higashi syndrome with an earlier-onset neurodegenerative phenotype.

Communications biology·2025

Related Experiment Video

Updated: Sep 7, 2025

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.9K

Baz1b Dosage Influences Cardiovascular Function, Predisposing to Dilated Cardiomyopathy.

Basil McIntosh1, Russell Knutsen1, Mark Levin1

  • 1Laboratory of Vascular and Matrix Genetics, National Heart, Lung, and Blood Institute, Bethesda, MD.

FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|June 20, 2022
PubMed
Summary
This summary is machine-generated.

Loss of BAZ1B gene function in mice leads to early death, reduced growth, and dilated cardiomyopathy. This suggests BAZ1B dosage is critical for development and cardiac health.

More Related Videos

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
13:42

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes

Published on: March 8, 2013

12.0K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K

Related Experiment Videos

Last Updated: Sep 7, 2025

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.9K
Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
13:42

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes

Published on: March 8, 2013

12.0K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K

Area of Science:

  • Genetics
  • Developmental Biology
  • Cardiology

Background:

  • BAZ1B (Williams Syndrome Transcription Factor) is implicated in neural crest cell migration and is deleted in Williams-Beuren Syndrome.
  • Understanding BAZ1B's role is crucial given its association with a complex genetic disorder affecting development.

Purpose of the Study:

  • To investigate the physiological consequences of BAZ1B loss-of-function using a mouse model.
  • To determine the impact of BAZ1B dosage on survival, growth, and cardiac function.

Main Methods:

  • Utilized a "knockout first" Baz1b mouse model (Baz1btm2a(KOMP)Wtsi) to assess gene expression and phenotype.
  • Conducted survival analysis, weight monitoring, microCT, and echocardiography on mutant and wildtype mice.

Main Results:

  • Baz1b mutant mice exhibited reduced gene expression, increased mortality (3x in heterozygotes, 16x in homozygotes), and significantly lower body weight compared to wildtypes.
  • Echocardiography revealed mildly decreased ejection fraction and fractional shortening, with increased left ventricular internal dimension in heterozygous mutants, indicative of dilated cardiomyopathy.

Conclusions:

  • BAZ1B dosage is critical for normal somatic growth and survival in mice.
  • Loss of BAZ1B function leads to dilated cardiomyopathy and contributes to growth failure and early mortality.
  • Further studies with conditional alleles are needed to elucidate mechanisms of growth and cardiac phenotypes.